Galderma, an emerging leader in the pure-play dermatology category, announced that it has received approval from Health Canada for Restylane Shaype, an injectable hyaluronic acid (HA) solution for temporary augmentation of the chin area. Restylane...
Ionis Pharmaceuticals said the drug to treat this rare genetic disease met the primary goal of a late-stage study. The drug donidalorsene reduced the number of seizures in patients with hereditary angioedema better than placebo. They were treated...
Pioneering clinical-stage biotechnology company Sensorion announces that it has received approval for its Clinical Trial Application (CTA) to initiate a Phase 1/2 clinical trial of SENS-501 (OTOF-GT) in France. The conclusion of Part I of the...
Sandoz, a key producer of generics and biosimilars, announced that it has signed an agreement to acquire US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. For $170 million in cash. According to the company’s...
The Ram Mandir Prathistha or consecration ceremony will begin in Ayodhya between 12:05 PM and 1:00 PM with Prime Minister Narendra Modi presiding over the ceremony. Prime Minister Narendra Modi is set to participate in...
Indian Immunologicals Ltd (IIL), a wholly owned subsidiary of the National Dairy Development Board (NDDB) and a biopharmaceutical company, has launched India's first hepatitis A vaccine 'Havisure'. This vaccine is a major step forward in the fight...
The Department of Pharmaceuticals has proposed to provide financial support to Micro, Small and Medium Enterprises (MSME) to help them upgrade their equipment to ensure better quality of medicines. "Under a central scheme, which is called...
The European Medicines Agency (EMA) has approved Synendos Therapeutics AG (Synendos), a global leader in cutting-edge Endocannabinoid System (ECS) treatments, to begin the phase 1 "first-in-human" clinical trial of its lead asset, SYT-510, a...
Amplia Therapeutics Limited reported that the US FDA has approved Amplia's IND application for a pancreatic cancer trial using their best-in-class focal adhesion kinase (FAK) inhibitor, narmafotinib. The proposed trial will investigate the safety...
DiagnaMed Holdings Corp announced the pilot launch of Cervai, a world-first consumer brain health and wellness AI solution that aims to 'raise a red flag' for potential brain health issues by estimating brain age and providing a brain health score...
, CDSCO.jpg)
.jpg)